Several other SHH/HH signalling inhibitors were approved or were under experimental investigation as cancer treatments including the GLI inhibitors arsenic trioxide and GANT-61 [122], the Shh palmitoylation inhibitor RU-SKI 43 [123], and the monoclonal antibodies that block SHH binding/function [124]. This evidence concerns the gene GLI1 and cancer.